TransMedics Group (NASDAQ:TMDX) Shares Up 7.4% – What’s Next?

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) traded up 7.4% on Wednesday . The stock traded as high as $73.59 and last traded at $73.30. 870,970 shares were traded during mid-day trading, a decline of 34% from the average session volume of 1,319,089 shares. The stock had previously closed at $68.27.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on TMDX shares. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research report on Wednesday, March 26th. Piper Sandler dropped their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Canaccord Genuity Group restated a “buy” rating and set a $104.00 target price on shares of TransMedics Group in a research report on Tuesday, March 11th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 target price (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Finally, Robert W. Baird decreased their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Price Performance

The firm has a 50 day moving average price of $69.93 and a two-hundred day moving average price of $86.32. The company has a market cap of $2.28 billion, a P/E ratio of 71.99 and a beta of 2.14. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in TransMedics Group in the 4th quarter worth approximately $4,131,000. Mackenzie Financial Corp lifted its position in shares of TransMedics Group by 73.0% during the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock worth $51,635,000 after acquiring an additional 349,403 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of TransMedics Group in the fourth quarter valued at $1,436,000. Pacific Point Advisors LLC bought a new stake in shares of TransMedics Group during the 4th quarter valued at $561,000. Finally, Palisades Investment Partners LLC raised its stake in shares of TransMedics Group by 7.6% during the 4th quarter. Palisades Investment Partners LLC now owns 160,108 shares of the company’s stock valued at $9,983,000 after purchasing an additional 11,323 shares during the period. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.